The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XV.e

Path: ILD with a granulomatous component (see also Im)

Publications

Castelli G, Maggioni G, El Mnif O, Calabrese F, Balestro E

Everolimus-induced granulomatous interstitial lung disease: a star to guide your way.

Thorax. 2026

Saito Y, Terasaki Y, Kashiwada T, Tanaka T, Takei H, Kimura G, Kondo Y, Kawagoe T, Matsushita A, Noro R, Minegishi Y, Kamio K, Seike M, Gemma A

Clinicopathological Characteristics of Everolimus-Associated Interstitial Lung Disease: A Single-Center Consecutive Analysis.

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi. 2024;91(2):207-217

Saito Y, Kunugi S, Suzuki Y, Narita K, Miura Y, Minegishi Y, Kimura G, Kondo Y, Azuma A, Fukuda Y, Gemma A

Granuloma-forming interstitial pneumonia occurring one year after the start of everolimus therapy.

Internal medicine (Tokyo, Japan). 2013;52(2):263-7